Summary

After a first episode of unprovoked pulmonary embolism initially treated during 6 months, extending anticoagulant therapy with warfarin for an additional 18 months significantly reduces the risk of recurrent venous thromboembolism. However, by 2 years after therapy is discontinued, the risk of recurrent thrombolic events is no different between the warfarin treatment group and the placebo group.